Iadademstat

Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome

What's the purpose of the trial?

This is a phase I study with a primary objective of determining the recommended phase II dose of iadademstat with azacitidine in adult subjects with myelodysplastic syndrome (MDS).

Trial status

Not yet accepting

Phase

Phase 1

Enrollment

Last Updated

1 month ago

Patient Screener

For Healthcare Professionals Only

This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.

View Patient Portal

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

Azacitidine is a type of chemotherapy called a hypomethylating agent that interferes with the growth and spread of cancer cells in the body.
Iadademstat

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Dose level -1

Accepting patients

Dose level 0

Accepting patients

Dose level 1

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.